← Leaderboards
Warren K Bickel
University Of Vermont &St Agric College
$43,729,025
Attributed
$53,294,083
Total exposure
30
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,294,083 · 30
By mechanism
R01$38,133,659 · 14
P01$3,797,645 · 4
R37$2,443,200 · 1
UH2$2,417,153 · 1
UH3$2,047,702 · 1
U19$1,717,995 · 1
Top collaborators
- Stephen M Laconte11 shared
- Leonard H Epstein7 shared
- P Read Montague5 shared
- Colleen A Hanlon4 shared
- Mikhail Nikolaas Koffarnus3 shared
- Merideth A. Addicott1 shared
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantPharmaceutical PreparationsAddictionBaseFutureBehavioralBehaviorDiscountingLaboratoriesSpecific Qualifier ValueHuman SubjectReinforcerEnvironmentSmokingTobaccoBrainSmokerCigaretteExhibitsEconomicsComplexPrefrontal CortexLearningRelating To Nervous System
Grant awards (127)
The Experimental Tobacco Marketplace (ETM)$78,902
P01 · FY2025 · CA · contact PI
Longitudinal Study of Recovery: Psychosocial Functioning, Relapse, and Neuro-Behavioral Markers$709,584
R01 · FY2023 · AA · contact PI
An Experimental Medicine Approach for the Mechanistic Understanding of Cocaine Use Disorder: Reinforcer Pathology$709,490
R01 · FY2023 · DA · contact PI
Experimental Tobacco Marketplace: Forecasting the Health Equity of Novel Tax Proposals$660,721
R01 · FY2023 · CA · contact PI
The Experimental Tobacco Marketplace (ETM)$143,949
P01 · FY2023 · CA · contact PI
Longitudinal Study of Recovery: Psychosocial Functioning, Relapse, and Neuro-Behavioral Markers$725,202
R01 · FY2022 · AA · contact PI
An Experimental Medicine Approach for the Mechanistic Understanding of Cocaine Use Disorder: Reinforcer Pathology$718,845
R01 · FY2022 · DA · contact PI
Experimental Tobacco Marketplace: Forecasting the Health Equity of Novel Tax Proposals$694,888
R01 · FY2022 · CA · contact PI
Testing Reinforcer Pathology: Mechanisms and Interventions to Change Alcohol Valuation$669,940
R01 · FY2022 · AA · contact PI
The Experimental Tobacco Marketplace (ETM)$160,850
P01 · FY2022 · CA · contact PI
Testing Reinforcer Pathology: Mechanisms and Interventions to Change Alcohol Valuation$684,887
R01 · FY2021 · AA · contact PI
Translational approaches to TMS treatment development for smoking$625,274
R01 · FY2021 · DA
Project 3: The abuse liability and substitution profile of removing cigarette ventilation in the experimental tobacco marketplace$361,124
P01 · FY2021 · CA · contact PI
The Experimental Tobacco Marketplace (ETM)$140,755
P01 · FY2021 · CA · contact PI
Testing Reinforcer Pathology: Mechanisms and Interventions to Change Alcohol Valuation$709,520
R01 · FY2020 · AA · contact PI
Translational approaches to TMS treatment development for smoking$623,712
R01 · FY2020 · DA
The Experimental Tobacco Marketplace (ETM)$369,461
P01 · FY2020 · CA · contact PI
Project 3: The abuse liability and substitution profile of removing cigarette ventilation in the experimental tobacco marketplace$300,484
P01 · FY2020 · CA · contact PI
Delay discounting as a target for self-regulation in prediabetes$969,273
UH3 · FY2019 · DK
Testing Reinforcer Pathology: Mechanisms and Interventions to Change Alcohol Valuation$734,354
R01 · FY2019 · AA · contact PI
Translational approaches to TMS treatment development for smoking$526,644
R01 · FY2019 · DA
The Experimental Tobacco Marketplace (ETM)$338,678
P01 · FY2019 · CA · contact PI
Project 3: The abuse liability and substitution profile of removing cigarette ventilation in the experimental tobacco marketplace$272,136
P01 · FY2019 · CA · contact PI
Translational approaches to TMS treatment development for smoking$121,740
R01 · FY2019 · DA
Delay discounting as a target for self-regulation in prediabetes$115,215
UH3 · FY2019 · DK
Delay discounting as a target for self-regulation in prediabetes$963,214
UH3 · FY2018 · DK
Translational approaches to TMS treatment development for smoking$632,938
R01 · FY2018 · DA
Abuse liability of reduced nicotine content cigarettes within a complex tobacco marketplace$486,138
R01 · FY2018 · DA · contact PI
The Experimental Tobacco Marketplace (ETM)$359,289
P01 · FY2018 · CA · contact PI
Project 3: The abuse liability and substitution profile of removing cigarette ventilation in the experimental tobacco marketplace$163,273
P01 · FY2018 · CA · contact PI
The Experimental Tobacco Marketplace (ETM)$116,638
P01 · FY2018 · CA · contact PI
Delay discounting as a target for self-regulation in prediabetes$764,505
UH2 · FY2017 · DK
Self-Control Improvement Intervention (SCII): Improving Abstinence in Smokers$631,864
R01 · FY2017 · DA · contact PI
The Repair of Self Control in Alcohol Dependence: Working Memory & Real Time fMRI$548,292
R01 · FY2017 · AA · contact PI
Abuse liability of reduced nicotine content cigarettes within a complex tobacco marketplace$472,123
R01 · FY2017 · DA · contact PI
Project 3: The abuse liability and substitution profile of removing cigarette ventilation in the experimental tobacco marketplace$399,540
P01 · FY2017 · CA · contact PI
The Experimental Tobacco Marketplace (ETM)$251,191
P01 · FY2017 · CA · contact PI
Delay discounting as a target for self-regulation in prediabetes$710,573
UH2 · FY2016 · DK
Self-Control Improvement Intervention (SCII): Improving Abstinence in Smokers$709,694
R01 · FY2016 · DA · contact PI
The Repair of Self Control in Alcohol Dependence: Working Memory & Real Time fMRI$548,292
R01 · FY2016 · AA · contact PI
The Social Interactome of Recovery: Social Media as Therapy Development$546,112
R01 · FY2016 · DA · contact PI
Abuse liability of reduced nicotine content cigarettes within a complex tobacco marketplace$528,640
R01 · FY2016 · DA · contact PI
The Experimental Tobacco Marketplace (ETM)$341,375
P01 · FY2016 · CA · contact PI
Delay discounting as a target for self-regulation in prediabetes$50,000
UH2 · FY2016 · DK
Delay discounting as a target for self-regulation in prediabetes$892,075
UH2 · FY2015 · DK
Self-Control Improvement Intervention (SCII): Improving Abstinence in Smokers$789,819
R01 · FY2015 · DA · contact PI
The Repair of Self Control in Alcohol Dependence: Working Memory & Real Time fMRI$557,036
R01 · FY2015 · AA · contact PI
The Social Interactome of Recovery: Social Media as Therapy Development$549,779
R01 · FY2015 · DA · contact PI
Behavioral Economic Methods for Assessing Tobacco Product Abuse Liability$422,834
U19 · FY2015 · CA · contact PI
Self-Control Improvement Intervention (SCII): Improving Abstinence in Smokers$806,528
R01 · FY2014 · DA · contact PI
Inter-Temporal Trade-offs in the Risky Decisions of Cocaine Addicts$719,325
R01 · FY2014 · DA · contact PI
The Social Interactome of Recovery: Social Media as Therapy Development$564,661
R01 · FY2014 · DA · contact PI
The Repair of Self Control in Alcohol Dependence: Working Memory & Real Time fMRI$563,091
R01 · FY2014 · AA · contact PI
Behavioral Economic Methods for Assessing Tobacco Product Abuse Liability$392,149
U19 · FY2014 · CA · contact PI
Self-Control Improvement Intervention (SCII): Improving Abstinence in Smokers$40,205
R01 · FY2014 · DA · contact PI
Inter-Temporal Trade-offs in the Risky Decisions of Cocaine Addicts$692,582
R01 · FY2013 · DA · contact PI
The Repair of Self Control in Alcohol Dependence: Working Memory & Real Time fMRI$586,946
R01 · FY2013 · AA · contact PI
Self-Control Improvement Intervention (SCII): Improving Abstinence in Smokers$573,078
R01 · FY2013 · DA · contact PI
Behavioral Economic Methods for Assessing Tobacco Product Abuse Liability$504,095
U19 · FY2013 · CA · contact PI
Inter-Temporal Trade-offs in the Risky Decisions of Cocaine Addicts$732,228
R01 · FY2012 · DA · contact PI
Executive Function Therapy for Stimulant Addiction$581,748
R01 · FY2012 · DA · contact PI
Behavioral Economic Methods for Assessing Tobacco Product Abuse Liability$398,917
U19 · FY2012 · CA · contact PI
Inter-Temporal Trade-offs in the Risky Decisions of Cocaine Addicts$722,659
R01 · FY2011 · DA · contact PI
Executive Function Therapy for Stimulant Addiction$596,982
R01 · FY2011 · DA · contact PI
Inter-Temporal Trade-offs in the Risky Decisions of Cocaine Addicts$750,566
R01 · FY2010 · DA · contact PI
Executive Function Therapy for Stimulant Addiction$322,315
R01 · FY2010 · DA · contact PI
Executive Function Therapy for Stimulant Addiction$228,806
R01 · FY2010 · DA · contact PI
Improving Combined Buprenorphine-Behavioral Treatment$893,322
R01 · FY2009 · DA · contact PI
Executive Function Therapy for Stimulant Addiction$531,387
R01 · FY2009 · DA · contact PI
The Behavioral Economics of Relapse$373,204
R01 · FY2009 · DA · contact PI
Executive Function Therapy for Stimulant Addiction$189,334
R01 · FY2009 · DA · contact PI
Translational Training in Addiction$165,860
T32 · FY2009 · DA · contact PI
Executive Function Therapy for Stimulant Addiction$100,665
R01 · FY2009 · DA · contact PI
Improving Combined Buprenorphine-Behavioral Treatment$874,801
R01 · FY2008 · DA · contact PI
Executive Function Therapy for Stimulant Addiction$571,167
R01 · FY2008 · DA · contact PI
The Behavioral Economics of Relapse$376,959
R01 · FY2008 · DA · contact PI
The Behavioral Economics of Relapse$13,423
R01 · FY2008 · DA · contact PI
Improving Combined Buprenorphine-Behavioral Treatment$870,577
R01 · FY2007 · DA · contact PI
The Behavioral Economics of Relapse$355,000
R01 · FY2007 · DA · contact PI
BEHAVIORAL ECONOMICS OF DRUG CHOICE$302,944
R37 · FY2007 · DA · contact PI
Improving Combined Buprenorphine-Behavioral Treatment$870,464
R01 · FY2006 · DA · contact PI
Delay Discounting in Drug Dependence$311,992
R01 · FY2006 · DA · contact PI
BEHAVIORAL ECONOMICS OF DRUG CHOICE$311,992
R37 · FY2006 · DA · contact PI
Delay Discounting in Drug Dependence$6,156
R01 · FY2006 · DA · contact PI
Improving Combined Buprenorphine-Behavioral Treatment$872,638
R01 · FY2005 · DA
BEHAVIORAL ECONOMICS OF DRUG CHOICE$319,500
R37 · FY2005 · DA
Delay Discounting in Drug Dependence$319,500
R01 · FY2005 · DA
IMPROVING COMBINED BUPRENORPHINE-BEHAVIORAL TREATMENT$504,891
R01 · FY2004 · DA
IMPROVING COMBINED BUPRENORPHINE-BEHAVIORAL TREATMENT$439,873
R01 · FY2004 · DA
Delay Discounting in Drug Dependence$284,290
R01 · FY2004 · DA
BEHAVIORAL ECONOMICS OF DRUG CHOICE$188,384
R37 · FY2004 · DA
BEHAVIORAL ECONOMICS OF DRUG CHOICE$152,491
R37 · FY2004 · DA
Delay Discounting in Drug Dependence$56,585
R01 · FY2004 · DA
IMPROVING COMBINED BUPRENORPHINE-BEHAVIORAL TREATMENT$919,722
R01 · FY2003 · DA
BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE$358,906
T32 · FY2003 · DA
BEHAVIORAL ECONOMICS OF DRUG CHOICE$340,875
R37 · FY2003 · DA
Delay Discounting in Drug Dependence$303,000
R01 · FY2003 · DA
IMPROVING COMBINED BUPRENORPHINE-BEHAVIORAL TREATMENT$882,167
R01 · FY2002 · DA
IMPULSIVITY IN DRUG DEPENDENCE--DELAY DISCOUNTING$353,133
R01 · FY2002 · DA
BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE$338,838
T32 · FY2002 · DA
BEHAVIORAL ECONOMICS OF DRUG CHOICE$299,573
R37 · FY2002 · DA
PHYSIOLOGIC, PSYCHOMOTOR &SELF-REPORTED MORPHINE EFFECT$0
M01 · FY2002 · RR
SEROTONIN FUNCTION IN IMPULSIVE OPIOID DEPENDENT PTS$0
M01 · FY2002 · RR
IMPROVING COMBINED BUPRENORPHINE-BEHAVIORAL TREATMENT$848,795
R01 · FY2001 · DA
IMPULSIVITY IN DRUG DEPENDENCE--DELAY DISCOUNTING$349,242
R01 · FY2001 · DA
BEHAVIORAL ECONOMICS OF DRUG CHOICE$244,858
R37 · FY2001 · DA
BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE$153,358
T32 · FY2001 · DA
DRUG ABUSE PREVENTION: COMPUTER TECHNOLOGY APPLICATION$149,000
R42 · FY2001 · DA
DRUG ABUSE PREVENTION: COMPUTER TECHNOLOGY APPLICATION$145,327
R42 · FY2001 · DA
IMPULSIVITY IN DRUG DEPENDENCE--DELAY DISCOUNTING$87,802
R01 · FY2001 · DA
DRUG ABUSE PREVENTION: COMPUTER TECHNOLOGY APPLICATION$47,110
R42 · FY2001 · DA
BEHAVIORAL ECONOMICS OF DRUG CHOICE$44,855
R37 · FY2001 · DA
IMPROVING COMBINED BUPRENORPHINE-BEHAVIORAL TREATMENT$893,202
R01 · FY2000 · DA
DRUG ABUSE PREVENTION: COMPUTER TECHNOLOGY APPLICATION$417,671
R42 · FY2000 · DA
BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE$299,342
T32 · FY2000 · DA
IMPULSIVITY IN DRUG DEPENDENCE--DELAY DISCOUNTING$283,120
R01 · FY2000 · DA
BEHAVIORAL ECONOMICS OF DRUG CHOICE$237,728
R37 · FY2000 · DA
BUPRENORPHINE PHARMACOLOGY RELATED TO ADDICTION TREATMENT$187,536
M01 · FY2000 · RR
BUPRENORPHINE INDUCED SUPERSENSITIVITY TO HYDROMORPHONE$187,536
M01 · FY2000 · RR
FURTHER CHARACTERICATION OF AGONIST EFFECTS OF FLUMAZENIL$187,536
M01 · FY2000 · RR
BUPRENORPHINE PHARMACOLOGY RELATED TO ADDICTION TREATMENT$32,903
M01 · FY2000 · RR
BUPRENORPHINE INDUCED SUPERSENSITIVITY TO HYDROMORPHONE$32,903
M01 · FY2000 · RR
FURTHER CHARACTERICATION OF AGONIST EFFECTS OF FLUMAZENIL$32,903
M01 · FY2000 · RR
PHYSIOLOGIC, PSYCHOMOTOR &SELF-REPORTED MORPHINE EFFECT$0
M01 · FY2000 · RR
SEROTONIN FUNCTION IN IMPULSIVE OPIOID DEPENDENT PTS$0
M01 · FY2000 · RR
PHYSIOLOGIC, PSYCHOMOTOR &SELF-REPORTED MORPHINE EFFECT$0
M01 · FY2000 · RR
SEROTONIN FUNCTION IN IMPULSIVE OPIOID DEPENDENT PTS$0
M01 · FY2000 · RR